이사회의 결정
파론 제약 오이
("Faron 또는 "회사")
이사회의 결정
Company announcement, April 8, 2024 at 9:05 (EEST) / 7:05 AM (GMT) / 12:05 AM (EDT)
핀란드 투르쿠 / 매사추세츠주 보스턴 - The annual general meeting ("AGM") of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) took place on April 5, 2024 and after the AGM, the Board of Directors ("Board") convened.
Frank Armstrong and Erik Ostrowsi did not stand for re-election and thus their tenure in the Company Board of Directors ended at the end of the AGM on 5 April, 2024.
At the meeting of the Board held following the AGM, Tuomo Pätsi was elected as the Chair of the Board.
또한 이사회는 이사회 구성원 중에서 이사회 위원회의 의장과 기타 구성원을 다음과 같이 선출했습니다.
· Markku Jalkanen was elected the Chair of the Audit Committee and Marie-Louise Fjällskog and John Poulos were elected as members of the Audit Committee.
· Tuomo Pätsi was elected the Chair of the Nomination Committee and Markku Jalkanen and Christine Roth were elected as the other members of the Nomination Committee.
· John Poulos was elected as the Chair of the Remuneration Committee and Tuomo Pätsi and Christine Roth were elected as the other members of the Remuneration Committee.
· John Poulos was elected as the Chair of the Business Development Committee and Markku Jalkanen and Juho Jalkanen were elected as the other members of the Business Development Committee
자세한 내용은 다음으로 문의하십시오.
파론 제약
투자자 연락처
LifeSci Advisor
다니엘 페리
Managing Director
+1 (617) 430-7576
ICR 콘실리움
메리 제인 엘리엇, 데이빗 데일리, 린지 네빌
전화 : + 44 (0) 20 3709 5700
이메일: [이메일 보호]
Cairn Financial Advisers LLP, 노매드
샌디 제이미슨, 조 터너
전화번호: + 44 (0) 207 213 0880
껍질 사냥 LLP, Broker
크리스토퍼 골든, 제임스 스틸
전화번호: + 44 (0) 20 7418 8900
Sisu Partners Oy, Nasdaq First North의 공인 고문
주하 카르투넨
전화 : + 358 (0) 40 555 4727
유카 야르벨라
전화 : + 358 (0) 50 553 8990
Faron Pharmaceuticals Oy 소개
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments treatments and as a monotherapy in last line solid cancers. Further information is available at www.faron.com.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.